Re Agreement

Stem Cell Sciences plc
06 October 2005


FOR IMMEDIATE RELEASE

Contact:    Stem Cell Sciences         Weber Shandwick | Square Mile
            Hugh Ilyine                Yvonne Alexander
            t: 0131 662 9829           t: 020 7067 0725
                                       m: 07866 610682

     Stem Cell Sciences Announces Agreement with Chemicon International for
  Manufacturing and Marketing of Novel, Serum-free, Embryonic Stem Cell Media
                                        
EDINBURGH, SCOTLAND - October 6th, 2005 - Stem Cell Sciences plc (LSE: STEM)
announced today that it has signed an exclusive agreement with Chemicon
International Inc, a wholly owned subsidiary of Serologicals Corporation
(NASDAQ:SERO), for the manufacture and marketing of its novel embryonic stem
(ES) cell media to the research and drug discovery market. Under the terms of
the agreement, Stem Cell Sciences (SCS) will receive an upfront licence fee,
milestone payments related to technology transfer and scale-up, as well as
trade-mark and royalty payments based on product sales. The total maximum value
of the deal to SCS will be in excess of US$2.5 million over the next several
years.

SCS has developed a range of ES cell media products which offer substantial
improvements over current animal-serum based media available in the market.
SCS's ES cell media will change the convenience and reproducibility of growing
mouse embryonic stem cells, and is an important development in the area of stem
cell research. It will offer large-scale cell production capabilities, enabling
the wider application of stem cells in research for drug discovery including new
medicines targeting central nervous system (CNS) diseases such as Parkinson's
and Alzheimer's. The current embryonic stem cell growth media market is valued
in excess of US $20 million and is growing quickly.

"This agreement marks a significant milestone in the commercialisation of SCS's
proprietary technologies," said Peter Mountford, CEO of Stem Cell Sciences.
"Chemicon, a well-established stem cell solutions provider, is well positioned
to both manufacture and distribute SCS's ES cell media and leverage the market
opportunity within the global stem cell markets. This will provide SCS with
significant revenue streams from early sales of the products."

"Chemicon is excited to add these new ES cell culture media formulations to our
portfolio of innovative reagents and technologies for the global stem cell
research community," said Jeffrey D. Linton, President of Chemicon. "These new
media formulations will aid researchers in the passaging and selection of
mammalian ES cell lines. These new products will broaden the solutions already
being provided to thousands of ES cell researchers worldwide via our LIF and
ESGRO(R) product lines. In addition, we look forward to furthering our
collaboration with Stem Cell Sciences to co-develop and market additional
innovative ES cell products."

Dr Mountford added, "This agreement marks the beginning of our roll out of a
range of superior performance cell culture media products for mouse and human
stem cell research needs."

SCS has developed its new formulations on discoveries made at the world famous
Institute for Stem Cell Research, University of Edinburgh, led by Professor 
Austin Smith. Product testing in world leading laboratories has confirmed the 
formulation benefits. The new products will be launched globally once technology 
transfer and production scale-up have been completed between the parties.

About Stem Cell Sciences

Stem Cell Sciences (SCS) has been a leading company in the stem cell research
arena since 1994, focused on technologies to grow, differentiate, select and
purify embryonic stem cells. The SCS group has headquarters in Edinburgh, UK and
laboratories in Melbourne, Australia and Kobe, Japan. It is expanding its
operations from 2006 to Cambridge UK and the USA. The new UK site in Cambridge
will focus on automation of cell based drug discovery assays for the
pharmaceutical industry. The US expansion will initially be based on licensing
opportunities of key SCS technologies, including Stem Cell Selection and novel
Neural Stem cells reported in August this year. Stem Cell Sciences plc was
listed on the London AIM in July 2005.

SCS has a substantial portfolio of patents and patent applications, and long
term relationships with world leading stem cell research centres. It has four
business units: SC Proven, covering cell culture media and reagents; SC
Licensing for technology transfer to industry; SC Services for supply of cell in
wells to the pharmaceutical industry; and SC Therapies, concentrating on the
longer term development of cell based therapies.

For more information, please visit our website: www.stemcellsciences.com

About Chemicon International, Inc

Chemicon International, Inc. offers a broad range of research products,
including speciality reagents, kits, antibodies, and custom products and 
services, to customers working in the areas of neuroscience, stem cell biology, 
cancer, and infectious disease research. It is also a leading supplier of 
monoclonal antibodies, conjugates, antibody blends and molecular-based detection 
kits for use in diagnostic laboratories. Chemicon focuses on basic and 
biomedical research, drug discovery, and diagnostics, allowing it to serve 
thousands of customers worldwide in the academic, clinical, biotechnology, and 
pharmaceutical sectors. Acquired in 2003, Chemicon is a Serologicals company, 
based in Temecula, CA, USA.

For more information, please visit our website: www.chemicon.com










                      This information is provided by RNS
            The company news service from the London Stock Exchange